AbbVie Q1 adjusted EPS $2.65 (+7.7%), revenue $15.0B (+12.4%); raises FY2026 guidance

AbbVie Inc.

2026-Q1 EPS reported $0.39 vs consensus $2.65 ▼ miss (-85.3%)

GAAP diluted EPS $0.39, down 45.8%; adjusted EPS $2.65, up 7.7%, with $0.41 IPR&D headwind.
Net revenue $15.002B, +12.4% reported / +10.3% operational; immunology portfolio $7.290B (+16.4%).
Skyrizi $4.483B (+30.9%), Rinvoq $2.119B (+23.3%), Humira $688M (-38.6%); neuroscience +26%.
FY2026 adjusted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16.
FDA CRL for trenibotulinumtoxinE on manufacturing; no safety/efficacy issues; expects prompt refiling.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

AbbVie Inc. reported the first quarter ended March 31, 2026 results: revenue $15.002 billion, EPS $0.39. Guidance raised.

Period: the first quarter ended March 31, 2026
Revenue: $15.002 billion
EPS: $0.39
Guidance: raised
Result: reported results

Exact text from the filing

Delivers First-Quarter Net Revenues of $15.002 Billion, an Increase of 12.4 Percent on a Reported Basis or 10.3 Percent on an Operational Basis

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

AbbVie Inc. filing history →

Source: SEC EDGAR

accession 0001551152-26-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.